BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 23589673)

  • 1. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis.
    Gadner H; Minkov M; Grois N; Pötschger U; Thiem E; Aricò M; Astigarraga I; Braier J; Donadieu J; Henter JI; Janka-Schaub G; McClain KL; Weitzman S; Windebank K; Ladisch S;
    Blood; 2013 Jun; 121(25):5006-14. PubMed ID: 23589673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Langerhans cell histiocytosis with a modified risk-adapted protocol-experience from a tertiary cancer institute in India.
    Narula G; Pradhan ND; Arora B; Banavali SD
    Pediatr Blood Cancer; 2018 Aug; 65(8):e27028. PubMed ID: 29512864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multisystem Langerhans cell histiocytosis in children: current treatment and future directions.
    Minkov M
    Paediatr Drugs; 2011 Apr; 13(2):75-86. PubMed ID: 21351807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification.
    Gadner H; Grois N; Pötschger U; Minkov M; Aricò M; Braier J; Broadbent V; Donadieu J; Henter JI; McCarter R; Ladisch S;
    Blood; 2008 Mar; 111(5):2556-62. PubMed ID: 18089850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment strategy for disseminated Langerhans cell histiocytosis. DAL HX-83 Study Group.
    Gadner H; Heitger A; Grois N; Gatterer-Menz I; Ladisch S
    Med Pediatr Oncol; 1994; 23(2):72-80. PubMed ID: 8202045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment results of Langerhans cell histiocytosis with LSH II protocol].
    Mottl H; Ganevová M; Radvanská J; Chánová M; Smelhaus V; Kodet R; Mrhalová M; Tichý M
    Cas Lek Cesk; 2005; 144(11):753-5. PubMed ID: 16335702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group.
    Minkov M; Grois N; Heitger A; Pötschger U; Westermeier T; Gadner H
    Klin Padiatr; 2000; 212(4):139-44. PubMed ID: 10994540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of High-risk Langerhans Cell Histiocytosis (LCH) in Egyptian Children, Does Intermediate-dose Methotrexate Improve the Outcome?
    Sedky MS; Hamouda A; Taha H; Zaky I; Hassanain O; El Hemaly A; ElHaddad A
    J Pediatr Hematol Oncol; 2019 Nov; 41(8):635-643. PubMed ID: 30247183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Egyptian experience in Langerhans cells histiocytosis: frequent multisystem affection and reactivation rates.
    Tantawy AAG; Ragab IA; Elsherif NHK; Makkeyah SM; AbdelRaheem HG; Elsantiel HIE
    Pediatr Hematol Oncol; 2020 Nov; 37(8):696-706. PubMed ID: 32706277
    [No Abstract]   [Full Text] [Related]  

  • 10. Langerhans Cell Histiocytosis (LCH) in Egyptian Children: Does Reactivation Affect the Outcome?
    Sedky MS; Rahman HA; Moussa E; Taha H; Raafat T; Hassanein O
    Indian J Pediatr; 2016 Mar; 83(3):214-9. PubMed ID: 26133729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vinblastine chemotherapy in adult patients with langerhans cell histiocytosis: a multicenter retrospective study.
    Tazi A; Lorillon G; Haroche J; Neel A; Dominique S; Aouba A; Bouaziz JD; de Margerie-Melon C; Bugnet E; Cottin V; Comont T; Lavigne C; Kahn JE; Donadieu J; Chevret S
    Orphanet J Rare Dis; 2017 May; 12(1):95. PubMed ID: 28532436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.
    Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ
    Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study.
    Morimoto A; Shioda Y; Imamura T; Kudo K; Kawaguchi H; Sakashita K; Yasui M; Koga Y; Kobayashi R; Ishii E; Fujimoto J; Horibe K; Bessho F; Tsunematsu Y; Imashuku S
    Int J Hematol; 2016 Jul; 104(1):99-109. PubMed ID: 27040279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating cell-free BRAF
    Héritier S; Hélias-Rodzewicz Z; Lapillonne H; Terrones N; Garrigou S; Normand C; Barkaoui MA; Miron J; Plat G; Aladjidi N; Pagnier A; Deville A; Gillibert-Yvert M; Moshous D; Lefèvre-Utile A; Lutun A; Paillard C; Thomas C; Jeziorski E; Nizard P; Taly V; Emile JF; Donadieu J
    Br J Haematol; 2017 Aug; 178(3):457-467. PubMed ID: 28444728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2'-Chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). results of the LCH-S-98 protocol of the Histiocyte Society.
    Weitzman S; Braier J; Donadieu J; Egeler RM; Grois N; Ladisch S; Pötschger U; Webb D; Whitlock J; Arceci RJ
    Pediatr Blood Cancer; 2009 Dec; 53(7):1271-6. PubMed ID: 19731321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of vindesine and prednisone and cyclophosphamide, etoposide, vindesine, and prednisone as first-line treatment for adult Langerhans cell histiocytosis: A single-center retrospective study.
    Duan MH; Han X; Li J; Zhang W; Zhu TN; Han B; Zhuang JL; Wang SJ; Cao XX; Cai HC; Chen M; Yang C; Zhou DB
    Leuk Res; 2016 Mar; 42():43-6. PubMed ID: 26859782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of children younger than 24 months with langerhans cell histiocytosis and bone involvement: a report from a single institution.
    Kamath S; Arkader A; Jubran RF
    J Pediatr Orthop; 2014 Dec; 34(8):825-30. PubMed ID: 25387157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes and prognostic risk factors of Langerhans cell histiocytosis in children: Results from the BCH-LCH 2014 protocol study.
    Cui L; Wang CJ; Lian HY; Zhang L; Ma HH; Wang D; Chen FF; Zhang Q; Yang Y; Wei A; Huang XT; Zhu T; Wang TY; Li ZG; Zhang R
    Am J Hematol; 2023 Apr; 98(4):598-607. PubMed ID: 36594188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic outcome of multifocal Langerhans cell histiocytosis in adults treated with the Special C regimen formulated by the Japan LCH Study Group.
    Morimoto A; Shimazaki C; Takahashi S; Yoshikawa K; Nishimura R; Wakita H; Kobayashi Y; Kanegane H; Tojo A; Imamura T; Imashuku S;
    Int J Hematol; 2013 Jan; 97(1):103-8. PubMed ID: 23243004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastrointestinal lesion in adult-onset Langerhans cell histiocytosis.
    Matsubara Y; Kobayashi M; Hijikata Y; Ota Y; Hirata Y; Lim LA; Yotsuyanagi H; Tojo A
    Int J Clin Oncol; 2020 Nov; 25(11):1945-1950. PubMed ID: 32901339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.